Gilead Sciences announced positive data regarding Livdelzi for PBC and bulevirtide for chronic HDV, underscoring progress in liver disease treatment. During the last quarter, the company also ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what you need to know. Gilead Sciences beat analysts’ revenue ...

On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) ($123 billion market cap) conducted its 2025 annual meeting of stockholders, with a quorum of over 1.1 billion shares represented. The biotech ...

Nikos Pekiaridis / NurPhoto via Getty Images Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined. The biopharma's profit got a lift from ...

Gilead Sciences reports quarterly earnings of $1.81 per share, which beat the analyst consensus estimate of $1.76. Quarterly revenue comes in at $6.67 billion, which missed the analyst ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Gilead Sciences. Looking at options history for Gilead Sciences GILD we detected 11 trades. If we consider the ...

Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Investing.com -- Gilead Sciences Inc . (NASDAQ:GILD) reported first quarter earnings that beat expectations, but shares fell over 4% in pre-open trading as revenue came in below analyst estimates.

Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest ...